SCHEMBL3904385

SCHEMBL3904385

CS(=O)(=O)NCc1cccc2cc(NS(=O)(=O)c3ccccc3)ccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 1/20 0.46
ALOX12 P18054 2/20 0.46
AKR1C3 P42330 1/20 0.45
NQO2 P16083 1/20 0.45
BRD4 O60885 1/20 0.44
BRD1 O95696 1/20 0.44
BRPF1 P55201 1/20 0.44
BRD9 Q9H8M2 1/20 0.44
BRPF3 Q9ULD4 1/20 0.44
HTR6 P50406 5/20 0.44
GAA P10253 2/20 0.44
HPGD P15428 2/20 0.44
ATM Q13315 1/20 0.44
CA2 P00918 1/20 0.44
PKM P14618 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3904466 0.90 ATM (0.50) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL3092172 0.84 NQO2 (0.48) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL3900248 0.81 LMNA (0.56) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL3958854 0.80 LMNA (0.48) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL3906058 0.80 CA1 (0.51) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL3976941 0.79 LMNA (0.47) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL3901359 0.77 MAPT (0.46) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL27756096 0.77 LMNA (0.45) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL27776906 0.77 LMNA (0.45) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL31594624 0.77 NQO2 (0.71) MEN1KMT2AMAPTNQO2ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076489-A1 ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF F. Hoffmann-Roche AG (CH) 2009-07-08 EP disclosed
US-7531577-B2 Arylsulfonamidyl tetralin derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2009-05-12 US disclosed
US-7531577-B2 Arylsulfonamidyl tetralin derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2009-05-12 US disclosed
US-7531577-B2 Arylsulfonamidyl tetralin derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2009-05-12 US disclosed
US-20080015208-A1 Arylsulfonamidyl tetralin derivatives and uses thereof ROCHE PALO ALTO LLC 2008-01-17 US disclosed
US-20080015208-A1 Arylsulfonamidyl tetralin derivatives and uses thereof ROCHE PALO ALTO LLC 2008-01-17 US disclosed
US-20080015208-A1 Arylsulfonamidyl tetralin derivatives and uses thereof ROCHE PALO ALTO LLC 2008-01-17 US disclosed
WO-2007147762-A1 ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2007-12-27 WO disclosed
WO-2007147762-A1 ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015208-A1 Arylsulfonamidyl tetralin derivatives and uses thereof HTR6, TPH1, HTR1B LMNA 2866/4885SMN1; SMN2 825/4885ALDH1A1 737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.